NASDAQ:INVA Innoviva (INVA) Stock Forecast, Price & News $13.06 -0.14 (-1.06%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$13.03▼$13.3150-Day Range$11.15▼$13.6452-Week Range$10.64▼$15.67Volume648,552 shsAverage Volume698,768 shsMarket Capitalization$911.33 millionP/E Ratio5.70Dividend YieldN/APrice Target$15.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Innoviva MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.1% Upside$15.17 Price TargetShort InterestBearish13.89% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment1.26Based on 8 Articles This WeekInsider TradingAcquiring Shares$6.48 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector734th out of 981 stocksPharmaceutical Preparations Industry355th out of 464 stocks 2.0 Analyst's Opinion Consensus RatingInnoviva has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.17, Innoviva has a forecasted upside of 16.1% from its current price of $13.06.Amount of Analyst CoverageInnoviva has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.89% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently increased by 1.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 3.5 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Innoviva this week, compared to 2 articles on an average week.Search InterestOnly 20 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows5 people have added Innoviva to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,480,410.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Innoviva is held by insiders. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 5.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 5.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.14.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Innoviva (NASDAQ:INVA) StockInnoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.Read More Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address INVA Stock News HeadlinesJune 6, 2023 | finance.yahoo.comInnoviva to Participate in the Goldman Sachs Annual Global Healthcare ConferenceJune 2, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Shares Up 3.5% on Insider Buying ActivityJune 6, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.June 1, 2023 | americanbankingnews.comAlexander J. Denner Acquires 50,000 Shares of Innoviva, Inc. (NASDAQ:INVA) StockJune 1, 2023 | americanbankingnews.comAlexander J. Denner Purchases 120,000 Shares of Innoviva, Inc. (NASDAQ:INVA) StockMay 23, 2023 | finance.yahoo.comInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous UseMay 22, 2023 | americanbankingnews.comInnoviva, Inc. (NASDAQ:INVA) Major Shareholder Acquires $653,500.00 in StockMay 18, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Shares Up 3.3% Following Insider Buying ActivityJune 6, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 17, 2023 | americanbankingnews.comAlexander J. Denner Purchases 290,000 Shares of Innoviva, Inc. (NASDAQ:INVA) StockMay 12, 2023 | msn.comEF Hutton Reiterates Innoviva (INVA) Buy RecommendationMay 12, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Upgraded by StockNews.com to BuyMay 11, 2023 | finance.yahoo.comResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious DiseasesMay 11, 2023 | finance.yahoo.comIs There An Opportunity With Innoviva, Inc.'s (NASDAQ:INVA) 35% Undervaluation?May 9, 2023 | finance.yahoo.comInnoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressMay 7, 2023 | americanbankingnews.comFinancial Comparison: Clene (NASDAQ:CLNN) versus Innoviva (NASDAQ:INVA)April 28, 2023 | finance.yahoo.comInnoviva Announces Retirement of Board ChairmanApril 23, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Stock Rating Reaffirmed by EF Hutton Acquisition Co. IApril 21, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Stock Price Up 4%April 20, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Sees Large Volume IncreaseApril 19, 2023 | americanbankingnews.comInnoviva (NASDAQ:INVA) Shares Gap Up to $12.02April 18, 2023 | msn.comInnoviva Rises on Advisory Committee Backing for Bacterial Pneumonia TherapyApril 18, 2023 | finance.yahoo.comFDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial InfectionsApril 17, 2023 | marketwatch.comInnoviva Shares Rise 7% After Pneumonia Drug's Approval by FDA CommitteeApril 17, 2023 | reuters.comUS FDA panel backs Innoviva's drug for multidrug-resistant bacterial infectionsApril 17, 2023 | marketwatch.comInnoviva Shares Halted as FDA Panel Reviews Sulbactam-Durlobactam >INVAApril 17, 2023 | finance.yahoo.comIs Innoviva (INVA) Stock Undervalued Right Now?See More Headlines INVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Company Calendar Last Earnings10/27/2021Today6/06/2023Next Earnings (Estimated)7/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees5Year Founded1996Price Target and Rating Average Stock Price Forecast$15.17 High Stock Price Forecast$22.50 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+16.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$2.29 Trailing P/E Ratio5.70 Forward P/E RatioN/A P/E GrowthN/ANet Income$213.92 million Net Margins73.36% Pretax Margin89.21% Return on Equity18.46% Return on Assets8.93% Debt Debt-to-Equity Ratio0.79 Current Ratio7.77 Quick Ratio6.47 Sales & Book Value Annual Sales$331.34 million Price / Sales2.75 Cash Flow$2.30 per share Price / Cash Flow5.67 Book Value$8.11 per share Price / Book1.61Miscellaneous Outstanding Shares69,780,000Free Float68,806,000Market Cap$911.33 million OptionableOptionable Beta0.55 Social Links Key ExecutivesPavel RaifeldChief Executive OfficerMarianne ZhenSecretary & Chief Accounting OfficerKey CompetitorsOPKO HealthNASDAQ:OPKMannKindNASDAQ:MNKDLigand PharmaceuticalsNASDAQ:LGNDLexicon PharmaceuticalsNASDAQ:LXRXIntercept PharmaceuticalsNASDAQ:ICPTView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Sold 56,900 shares on 6/1/2023Ownership: 0.008%Alexander J DennerBought 120,000 shares on 5/30/2023Total: $1.56 M ($13.01/share)ProShare Advisors LLCSold 1,860 shares on 5/26/2023Ownership: 0.020%Alexander J DennerBought 50,000 shares on 5/25/2023Total: $654,500.00 ($13.09/share)Royce & Associates LPBought 18,054 shares on 5/23/2023Ownership: 0.168%View All Insider TransactionsView All Institutional Transactions INVA Stock - Frequently Asked Questions Should I buy or sell Innoviva stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares. View INVA analyst ratings or view top-rated stocks. What is Innoviva's stock price forecast for 2023? 3 brokers have issued twelve-month price targets for Innoviva's stock. Their INVA share price forecasts range from $10.00 to $22.50. On average, they expect the company's share price to reach $15.17 in the next year. This suggests a possible upside of 16.1% from the stock's current price. View analysts price targets for INVA or view top-rated stocks among Wall Street analysts. How have INVA shares performed in 2023? Innoviva's stock was trading at $13.25 at the start of the year. Since then, INVA shares have decreased by 1.4% and is now trading at $13.06. View the best growth stocks for 2023 here. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported $0.90 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.47. The biotechnology company earned $97.86 million during the quarter. Innoviva had a trailing twelve-month return on equity of 18.46% and a net margin of 73.36%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows 100 ETF (CALF), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Health Care ETF (PSCH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). What is Innoviva's stock symbol? Innoviva trades on the NASDAQ under the ticker symbol "INVA." Who are Innoviva's major shareholders? Innoviva's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.62%), Dimensional Fund Advisors LP (5.42%), State Street Corp (3.42%), Systematic Financial Management LP (3.21%), Westfield Capital Management Co. LP (2.52%) and Pacer Advisors Inc. (2.35%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Innoviva's stock price today? One share of INVA stock can currently be purchased for approximately $13.06. How much money does Innoviva make? Innoviva (NASDAQ:INVA) has a market capitalization of $911.33 million and generates $331.34 million in revenue each year. The biotechnology company earns $213.92 million in net income (profit) each year or $2.29 on an earnings per share basis. How can I contact Innoviva? Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690. This page (NASDAQ:INVA) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.